Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2010-07-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Controlled Trial on Visual Field Training
NCT01669031
Study on the Effectiveness and Safety of VRT in Patients With Visual Field Defects
NCT06914505
Non-inferiority Study for Visual Field Measurements Using a Virtual Reality Device
NCT04010383
Feasibility Test of Virtual Reality Obstacle Detection for Low Vision Walking
NCT05141604
Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)
NCT01372319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES: The investigators propose to test the hypothesis that a large portion of total perimetric variability in patients with visual loss is due to a poor signal-to-noise ratio associated with using a small fixed-size stimulus.
RESEARCH PLAN AND METHODS: To test this hypothesis, the investigators are examining patients with optic nerve diseases with conventional automated perimetry (size III) and tests having large-sized and scaled stimuli (size V, size VI (custom perimeter) and luminance size threshold perimetry - a test where threshold is found by changing stimulus size rather than stimulus intensity). Over four years the investigators will test 100 patients with and glaucoma and 60 normals each eight times. In addition, the investigators are retesting 50 subjects once a week for 5 weeks. The investigators are also studying the associated structural-functional correlations using OCT and developing a statistical model that accounts for correlations of neighboring test locations.
Perimetric variability and the reliable identification of visual field change is the single most difficult problem in visual testing today. The investigators anticipate identifying a method that allows efficient and accurate determination of visual field change. Identification of a superior method would (1) reduce the number of examinations needed, thereby reducing the costs of medical care; (2) minimize misdiagnosis, unnecessary testing and even unnecessary surgery that results from mistakenly interpreting fluctuation of the visual field as progression or improvement; (3) allow earlier disease intervention and (4) reduce the costs of clinical trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
glaucoma
Comparison of four visual field testing strategies
We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
Group 2
normal
Comparison of four visual field testing strategies
We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comparison of four visual field testing strategies
We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild cataract with VA of 20/30 or better pinholed
* Refractive error of = to or less than 6 diopters with = or less than 3.50 diopters of cylinder
* Pupil diameter of 3 mm minimum
* Controlled hypertension, diabetes, migraine
* Pseudophakic/refractive surgery if no vision problems
* Trabeculectomy okay
Exclusion Criteria
* History of stroke
* Systemic disease \[lupus, graves, cancer (within the last 5 yrs), AIDS, other\]
* History of amblyopia
* Unreliable patient
* Frequently misses appointments
* Tests poorly
* Ocular hypertension
* Retinal problems
* Diabetic retinopathy
* Neurological disease (IIH, ON, AION)
* Cancer not in remission for the last 5 years
* Vein or artery occlusions
* Macular degeneration
* Trauma with vision loss
* Ocular inflammation (pars planitis, iritis, temporal aeuritis)
18 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Wall, MD
Role: PRINCIPAL_INVESTIGATOR
Iowa City VA Health Care System, Iowa City, IA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iowa City VA Health Care System, Iowa City, IA
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wall M, Doyle CK, Eden T, Zamba KD, Johnson CA. Size threshold perimetry performs as well as conventional automated perimetry with stimulus sizes III, V, and VI for glaucomatous loss. Invest Ophthalmol Vis Sci. 2013 Jun 7;54(6):3975-83. doi: 10.1167/iovs.12-11300.
Kummet CM, Zamba KD, Doyle CK, Johnson CA, Wall M. Refinement of pointwise linear regression criteria for determining glaucoma progression. Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6234-41. doi: 10.1167/iovs.13-11680.
Wall M, Doyle CK, Zamba KD, Artes P, Johnson CA. The repeatability of mean defect with size III and size V standard automated perimetry. Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1345-51. doi: 10.1167/iovs.12-10299.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C7098-R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.